Table 2. Indicators of possible relevance to fluorescent tracers.
| Characteristics | Success (n=55) | Failure (n=14) | P value |
|---|---|---|---|
| Age (years) | 51.16±9.54 | 54.21±12.32 | 0.32 |
| BMI (kg/m2) | 23.87±3.57 | 25.18±4.15 | 0.24 |
| <24 | 35 (63.6) | 3 (21.4) | |
| ≥24 | 20 (36.4) | 11 (78.6) | |
| Tumor quadrant | 0.88 | ||
| UOQ | 14 (25.5) | 2 (14.2) | |
| OQT | 6 (10.9) | 3 (21.4) | |
| LOQ | 10 (18.2) | 4 (28.6) | |
| LQT | 4 (7.3) | 0 (0.0) | |
| LIQ | 5 (9.1) | 0 (0.0) | |
| IQT | 0 (0.0) | 0 (0.0) | |
| UIT | 8 (14.5) | 3 (21.4) | |
| UQT | 8 (14.5) | 2 (14.2) | |
| Tumor grade* | 0.31 | ||
| I | 11 (20.0) | 1 (7.1) | |
| II | 28 (50.9) | 7 (50.0) | |
| III | 12 (21.8) | 5 (35.7) | |
| Histologic type | 0.86 | ||
| IDC | 45 (81.8) | 11 (78.6) | |
| ILC | 3 (5.5) | 0 (0.0) | |
| CIS | 2 (3.6) | 0 (0.0) | |
| Other | 5 (9.1) | 3 (21.4) | |
| T | 0.24 | ||
| Tis | 2 (3.6) | 0 (0.0) | |
| T1 | 25 (45.5) | 10 (71.4) | |
| T2 | 27 (49.1) | 4 (28.6) | |
| T3 | 1 (1.8) | 0 (0.0) | |
| N | 0.98 | ||
| N0 | 43 (78.2) | 10 (71.4) | |
| N1 | 9 (16.4) | 4 (28.6) | |
| N2 | 2 (3.6) | 0 (0.0) | |
| N3 | 1 (1.8) | 0 (0.0) | |
| Carcinoma in situ components | 0.49 | ||
| Yes | 42 (76.4) | 11 (78.6) | |
| No | 13 (23.6) | 3 (21.4) | |
| Vascular invasion* | 0.66 | ||
| Yes | 11 (20.0) | 2 (14.2) | |
| No | 42 (76.4) | 12 (85.7) | |
| Neural invasion* | 0.57 | ||
| Yes | 6 (10.9) | 2 (14.2) | |
| No | 47 (85.5) | 12 (85.7) | |
| Molecular typing* | 0.49 | ||
| HR+/HER2− | 39 (70.9) | 10 (71.4) | |
| HR+/HER2+ | 5 (9.1) | 0 (0.0) | |
| Basal-like | 7 (12.7) | 3 (21.4) | |
| HR−/HER2+ | 2 (3.6) | 0 (0.0) | |
| ICG dose (mg/kg) | 0.66 | ||
| 0.5 | 16 (29.1) | 2 (14.2) | |
| 1 | 39 (70.9) | 12 (85.7) | |
Quantitative variables were described by mean ± standard deviation. Categorical variables were described as n (%). Group differences were compared using the ANOVA. Percentage totals may not add to 100% due to rounding. *, 2 cases of carcinoma in situ were not included in tumor grade, vascular invasion, neural invasion and molecular typing. One case of papillary carcinoma and 1 case of invasive carcinoma <0.1 cm were not included in tumor grade and molecular typing. One case of invasive carcinoma =0.1 cm was not included in tumor grade. BMI, body mass index; UOQ, upper outer quadrant; OQT, outer quadrant transition; LOQ, lower outer quadrant; LQT, lower quadrant transition; LIQ, lower inner quadrant; IQT, inner quadrant transition; UIT, upper inner transition; UQT, upper quadrant transition; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; CIS, carcinoma in situ; HR, hormone receptor; HER2, human epidermal growth factor 2; ICG, indocyanine green; ANOVA, one-way analysis of variance.